Axim Biotechnologies Inc (OTCMKTS:AXIM) has been one of our favorites in the MMJ space since the early Fall. That’s when the company’s research trajectory started to get serious traction in the development of a chewing gum delivery system for THC and CBD for the treatment of pain and spasticity associated with multiple sclerosis.
Recently, that success has begun to yield a virtuous circle of catalysts (which we will cover below), creating a ton of momentum in the shares. Recent action has seen nearly 110% tacked on to share pricing for the name in the past month. This is emblematic of the stock. AXIM has evidenced sudden upward volatility on many prior occasions. Furthermore, the listing has seen an influx in interest of late, with the stock’s recent average trading volume running 120% above its longer run average levels.
Axim Biotechnologies Inc (OTCMKTS:AXIM) bills itself as a biotechnology company that focuses on